NEW YORK (TheStreet) -- Ariad Pharmaceuticals (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement.
The proposal includes a 30-day option for initial buyers to purchase up to an additional $50 million aggregate principal amount under the same terms.
The stock was down 4.27% to $6.72 at 4:46 p.m.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts